Latest progress from PharmNovo at EFIC
PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.
“We are very much looking forward to the congress and to describe our latest progress. PharmNovo is at the forefront of the field, pioneering the development of a delta opioid agonist. At this stage, we are more than ready to present our successful outcomes to the meeting, and to share these with our peers, investors, and collaborators”, says PharmNovo's Founder and Scientific Advisor, Bengt von Mentzer.
Bengt von Mentzer will be presenting two posters on PharmNovo's PN6047, our innovative drug candidate for neuropathic pain:
- Toxicity and safety testing of PN6047 – a delta agonist
In preclinical studies, PN6047 is shown to be safe and well tolerated with a wide estimated therapeutic window and lacking abuse potential. Preliminary results from the human phase I study show a similar profile and strongly indicate that PN6047 will be safe and tolerable and able to enter phase II efficacy studies in neuropathic pain patients.
- Antitussive activity of delta opioid receptor agonists
New data indicate that delta opioid agonists could provide a potential novel therapy for chronic cough without the unwanted effects, such as reduced respiration, of conventional non-selective opioids.
“Our successful phase I study was executed with professionalism and speed. We have now passed several important milestones and are well on our way in our mission to launch PN6047 as a compound for treating neuropathic pain and other conditions involving hypersensitivity in the nervous system. We are excited to enter the next, phase 2, stage of clinical testing with the potential of providing a new therapy to the millions of people suffering from neuropathic pain” says Bengt von Mentzer.
The European Pain Federation EFIC is a non-profit organisation representing healthcare professionals in pain management and science.
To learn more about the Congress of the European Pain Federation and to explore the agenda for the world congress, visit: https://europeanpainfederation.eu/efic2023/
Latest progress from PharmNovo at EFIC
PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.
“We are very much looking forward to the congress and to describe our latest progress. PharmNovo is at the forefront of the field, pioneering the development of a delta opioid agonist. At this stage, we are more than ready to present our successful outcomes to the meeting, and to share these with our peers, investors, and collaborators”, says PharmNovo's Founder and Scientific Advisor, Bengt von Mentzer.
Bengt von Mentzer will be presenting two posters on PharmNovo's PN6047, our innovative drug candidate for neuropathic pain:
- Toxicity and safety testing of PN6047 – a delta agonist
In preclinical studies, PN6047 is shown to be safe and well tolerated with a wide estimated therapeutic window and lacking abuse potential. Preliminary results from the human phase I study show a similar profile and strongly indicate that PN6047 will be safe and tolerable and able to enter phase II efficacy studies in neuropathic pain patients.
- Antitussive activity of delta opioid receptor agonists
New data indicate that delta opioid agonists could provide a potential novel therapy for chronic cough without the unwanted effects, such as reduced respiration, of conventional non-selective opioids.
“Our successful phase I study was executed with professionalism and speed. We have now passed several important milestones and are well on our way in our mission to launch PN6047 as a compound for treating neuropathic pain and other conditions involving hypersensitivity in the nervous system. We are excited to enter the next, phase 2, stage of clinical testing with the potential of providing a new therapy to the millions of people suffering from neuropathic pain” says Bengt von Mentzer.
The European Pain Federation EFIC is a non-profit organisation representing healthcare professionals in pain management and science.
To learn more about the Congress of the European Pain Federation and to explore the agenda for the world congress, visit: https://europeanpainfederation.eu/efic2023/
Latest news
View all
Phase I study completed for PN6047
In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read more
PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read more
No abuse potential shown in preclinical studies
We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more